Advertisement

Topics

Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer Immunotherapies

08:00 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the completion of its Series B round of financing with a total investment...

Other Sources for this Article

Atreca, Inc.
Susan Berland
EVP and Chief Financial Officer
info@atreca.com
or
Media:
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com
or
Investors:
John Grimaldi, 212-213-0006, ext. 362
jgrimaldi@burnsmc.com

NEXT ARTICLE

More From BioPortfolio on "Atreca Completes Oversubscribed $35 Million Series B Financing to Advance Novel Cancer Immunotherapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...